RLMD - Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study | Benzinga
Relmada Therapeutics Inc (NASDAQ: RLMD) announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3 trial (Study 310) of REL-1017 in patients with Major Depressive Disorder (MDD).
Patients treated daily with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment.
REL-1017 was well-tolerated with long-term dosing, showing low rates of adverse events ...